The combination drug lopinavir-ritonavir is not recommended for hospitalized COVID-19 patients because it doesn't significantly shorten hospital stay or lower the risk of needing mechanical ventilation or of dying, according to a study yesterday in The Lancet.The ongoing University of Oxford–sponsored Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial involving coronavirus patients at 176 hospitals in the United Kingdom is the first known large, randomized, controlled trial to assess the effectiveness of lopinavir-ritonavir for this indication.The antiviral drug combination, approved by the US Food and Drug Administration to treat HIV/AIDS, has been recommended as a first- or second-line treatment for COVID-19 in many countries on